ArticleRSC advances2025
BSA-ICG-Cu(ii) complex as an NIR-responsive multifunctional platform for wound healing: deciphering therapeutic action
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic platforms suitable for NIR-responsive antimicrobial treatments through photothermal and photodynamic modalities are gaining attention in treating chronic wounds. The efficiency of such platforms can be further enhanced by making them angiogenic and a promoter of fibroblast activities. Herein, we report a novel molecular platform composed of bovine serum albumin (BSA), indocyanine green (ICG) and bivalent copper (Cu(ii)) using green chemistry by exploiting the affinity of ICG and Cu(ii) ions towards BSA. We hypothesized that in the BSA-ICG-Cu(ii) complex, ICG will help in producing heat and reactive oxygen species under NIR (808 nm) exposure, which can kill bacteria; Cu(ii) will induce angiogenesis and BSA will activate dermal fibroblasts. The SEM images of the BSA-ICG-Cu(ii) complex revealed a bead and fibril structure at the microscale. Biophysical studies (UV-vis-NIR, fluorescence and CD spectroscopy) indicated stable complex formation through the involvement of the hydrophobic BSA core. A study on NIR-mediated (808 nm LASER) killing of bacteria (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.